Allegan Plc said it is expecting its revenue to be greater than $8 billion in the 2nd-half to reflect the divesture of its global generics business to Teva Pharmaceuticals Industries Ltd.
The drugmaker said it plans to report its global generics business as discontinued operations in the 3rd-quarter.
The material has been provided by InstaForex Company – www.instaforex.com